Fluorimetric and chromatographic determination of pancuronium bromide and its metabolites in biological materials

Kersten, U.; Meijer, Dirk K. F.; Ágoston, S.

doi:10.1016/0009-8981(73)90160-5

Cited by 79 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis was carried out by a fluorimetric method combined with thin-layer chromatography (TLC), based on the method described for pancuronium bromide. 16 The detection limit of pipecuronium in plasma and urine was 25 ng.ml -I. The standard deviation of pipecuronium fluorescence of plasma levels in the range from 25 ng.…”

Section: Procedures Of the Kinetic Studymentioning

confidence: 88%

Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery

et al. 1990

View full text Add to dashboard Cite

Section: Procedures Of the Kinetic Studymentioning

confidence: 88%

Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery

et al. 1990

View full text Add to dashboard Cite

“…Recently, radioimmunoassay, fluorimetric and chromatographic techniques (Horowitz and Spector, 1973;Kersten, Meijer and Agoston, 1973) have greatly facilitated the determination of the serum concentration of the neuromuscular blockers. Readers interested in the principles of pharmacokinetics are referred to Greenblatt and Koch-Weser (1975), Hug (1978) and Hull (1979) for recent reviews.…”

Section: Pharmacokineticsmentioning

confidence: 99%

Neuromuscular Pharmacology

Lee

Katz

1980

British Journal of Anaesthesia

View full text Add to dashboard Cite

show abstract

“…The blood samples were centrifuged and the plasma separated and stored at -20°C until assayed. Total gallamine plasma concentrations were determined by modification of the spectrofluorimetric procedure of Kersten, Meijer & Agoston (1973) for pancuronium as modified for gallamine by Ramzan et al (1980a).…”

Section: Methodsmentioning

confidence: 99%

Gallamine disposition in surgical patients with chronic renal failure.

Ramzan¹,

Shanks²,

Triggs³

1981

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Plasma levels of gallamine and the elicited neuromuscular response have been measured in seven patients with compromised renal function who received a single 2 mg/kg dose and in a further patient who received an initial dose of 2 mg/kg followed by two additional doses of 1 mg/kg. 2 The plasma level-time data from all patients was adequately explained by a biexponential equation interpreted as a two-compartment open mammillary model. 3 Comparison of the model-independent pharmacokinetic parameters for gallamine between these patients and a group of normal patients revealed that the elimination phase half-life (T1 3) was significantly prolonged in renal failure with a marked reduction in the plasma clearance of gallamine. 4 Gallamine had larger apparent volumes of distribution in the presence of renal failure than those found in normal patients. 5 The peak paralysis levels attained and the associated plasma concentrations of gallamine were similar in patients with and without renal failure. 6 At this low dosage the rate of recovery from paralysis in renal failure patients, though similar to that noted normally, appeared to be somewhat slower in some patients. 7 The results suggest that gallamine is not to be preferred to other nondepolarizing muscle relaxants in patients with renal failure.

show abstract

Fluorimetric and chromatographic determination of pancuronium bromide and its metabolites in biological materials

Cited by 79 publications

References 0 publications

Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery

Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery

Neuromuscular Pharmacology

Gallamine disposition in surgical patients with chronic renal failure.

Contact Info

Product

Resources

About